A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
AbiVax obefazimod showed 39-40% Phase 3 remission—nearly double marketed IBD competitors (19-32%)—but cancer cases sent stock down 30%. FDA approval remains likely: Rinvoq precedent shows $8B+ sales persist despite boxed malignancy warnings.
An article from
Dive Brief
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
Published June 2, 2026
AbiVax shares tumbled on Phase 3 results in a form of inflammatory bowel disease.
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Abivax stock plunges on cancer signal in ulcerative colitis trial
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Why Is Abivax Stock Sinking Tuesday? - Abivax (NASDAQ:ABVX)
Abivax share plunge may change deal outlook
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Radiopharmaceutical shows promise in post-Pluvicto setting
A Parigi crolla Abivax, segnalati casi di cancro in studio clinico su farmaco
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
"The cancer signal complicates matters."
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't…
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares…
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative…
The drugmaker has been viewed as a near-term takeover target for Big Pharma.
